Altered dendritic cell phenotype in response to Leishmania amazonensis amastigote infection is mediated by MAP kinase, ERK

American Journal of Pathology

Volumn 174, Issue 5, 2009, Pages 1818-1826

  Boggiatto, Paola Mercedes ^a   Jie, Fei ^a   Ghosh, Mousumi ^a   Gibson Corley, Katherine Nicole ^a   Ramer Tait, Amanda Ellen ^b   Jones, Douglas Elliot ^a   Petersen, Christine Anne ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CD40 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 12P40; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOBLOTTING; LEISHMANIA; LEISHMANIASIS; LYMPH NODE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; C3H MOUSE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HOST PARASITE INTERACTION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PARASITOLOGY; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD40; BONE MARROW; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HOST-PARASITE INTERACTIONS; IMMUNOBLOTTING; LEISHMANIA; MICE; MICE, INBRED C3H; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; PHOSPHORYLATION;

EID: 65649113275     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080905     Document Type: Article

References (30)

1. Gregory DJ, Oliver M: Subversion of host cell signaling by the protozoan parasite Leishmania. Parasitology 2005, 130:27-35
2. Olivier M, Gregory DJ, Forget G: Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 2005, 18:293-305 (Pubitemid 40548295)
3. Reiner SL, Locksley RM: The regulation of immunity to Leishmania major. Annu Rev Immunol 1995, 13:151-177
4. Ji J, Sun J, Qi H, Soong L: Analysis of T helper cell responses during infection with Leishmania amazonensis. Am J Trop Med Hyg 2002, 66:338-345
5. Jones DE, Ackermann MR, Wille U, Hunter CA, Scott P: Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10- deficient mice does not lead to resolution of infection. Infect Immun 2002, 70:2151-2158 (Pubitemid 34242217)
6. Ramer AE, Vanloubbeeck YF, Jones DE: Antigen-responsive CD4+ T cells from C3H mice chronically Infected with Leishmania amazonensis are impaired in the transition to an effector phenotype. Infect Immun 2006, 74:1547-1554
7. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252 (Pubitemid 28155090)
8. Scott P: Experimental cutaneous leishmaniasis: induction and regulation of T cells following infection of mice with Leishmania major. Chem Immunol 1998, 70:60-80 (Pubitemid 28059686)
9. Kamanaka M, Yu P, Yasui T, Yoshida K, Kawabe T, Horii T, Kishimoto T, Kikutani H: Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 1996, 4:275-281 (Pubitemid 26131010)
10. Soong L, Xu JC, Grewal IS, Kima P, Sun J, Longley BJ Jr., Ruddle NH, McMahon-Pratt D, Flavell RA: Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 1996, 4:263-273 (Pubitemid 26131009)
11. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR: CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996, 4:283-289 (Pubitemid 26131011)
12. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, Gately MK, Louis JA, Alber G: Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996, 26:1553-1559 (Pubitemid 26230002)
13. Chakir H, Campos-Neto A, Mojibian M, Webb JR: IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response. Microbes Infect 2003, 5:241-249 (Pubitemid 36428713)
14. Xin L, Li Y, Soong L: Role of interleukin-1beta in activating the CD11c(high) CD45RB- dendritic cell subset and priming Leishmania amazonensis-specific CD4+ T cells in vitro and in vivo. Infect Immun 2007, 75:5018-5026 (Pubitemid 47502175)
15. Xin L, Li K, Soong L: Down-regulation of dendritic cell signaling pathways by Leishmania amazonensis amastigotes. Mol Immunol 2008, 45:3371-3382
16. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P: Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 1998, 188:2175-2180 (Pubitemid 28562533)
17. Puig-Kröger A, Relloso M, Fernández-Capetillo O, Zubiaga A, Silva A, Bernabéu C, Corbí AL: Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Immunobiology 2001, 98:2175-2182
18. Yang Z, Mosser DM, Zhang X: Activation of the MAPK. ERK, following Leishmania amazonensis infection of macrophages. J Immunol 2006, 178:1077-1085
19. Mukbel RM, Patten C, Gibson KN, Ghosh M, Petersen C, Jones DE: Macrophage killing of L. amazonensis amastigotes requires both nitric oxide and superoxide. Am Soc Trop Med Hyg 2007, 74:660-675
20. Nakahara T, Moroi Y, Uchi H, Furue M: Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci 2006, 42:1-11 (Pubitemid 43384125)
21. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92 (Pubitemid 29096240)
22. Jones DE, Buxbaum LU, Scott P: IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 2000, 165:364-372 (Pubitemid 30429528)
23. Iezzi G, Frohlich A, Ernst B, Ampenberger F, Saeland S, Glaichenhaus N, Kopf M: Lymph node resident rather than skin-derived dendritic cells initiate specific T cell responses after Leishmania major infection. J Immunol 2006, 177:1250-1256 (Pubitemid 44036630)
24. Kima P: The amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection and persist. Int J Parasitol 2007, 37:1087-1096 (Pubitemid 47042032)
25. Favali C, Tavares N, Clarêncio J, Barral A, Barral-Netto M, Brodskyn C: Leishmania amazonensis infection impairs differentiation and function of human dendritic cells. J Leuk Biol 2007, 82:1401-1406 (Pubitemid 350276951)
26. Chang L, Karin M: Mammalian MAP kinase signaling cascades. Nature 2001, 410:37-40 (Pubitemid 32225829)
27. Zhang Y, Dong C: MAP kinases in immune responses. Cell Mol Immunol 2005, 2:20-27
28. Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4:937-947 (Pubitemid 39626217)
29. Feng GJ, Goodridge HS, Harnett MM, Wei XQ, Nikolaev AV, Higson AP, Liew FY: Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunology 1999, 163:6403-6412
30. Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M: Development of a conditional In vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res 2005, 65:9962-9970 (Pubitemid 41541477)